Saturday 17 October 2026
Export CADL’s income statement to Excel — free account
Candel Therapeutics, Inc.
CADL Healthcare Biotechnology
Candel Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $125,000.00. In the quarter to June 2026, EPS fell 477.8%, free cash flow fell 93.4% and total debt rose 525.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
8.19
0.72
−8.08%
Follow CADL
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 5.51 | 1.40 | 0.66 | 1.16 | 4.25 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 14.78 | 8.10 | 3.06 | 14.60 | 13.68 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 50 | 65 | 76 | 42 | 38 | 55 | ||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | 0 | 0 | 0 | 0 | — | — | — | ||||
| Gross margin, % | — | — | — | 0.00 | 100.00 | 100.00 | 100.00 | — | — | — | |||||
| EBT | — | — | — | (8) | (18) | (36) | (19) | (38) | (55) | (38) | |||||
| EBT margin, % | — | — | — | (6,592.00) | (14,144.00) | (28,899.20) | (15,035.20) | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | (8) | (18) | (36) | (19) | (38) | (55) | (38) | |||||
| Depreciation | — | — | — | 0 | 0 | 0 | 1 | 1 | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | (0.28) | (1.52) | (1.91) | (0.65) | (1.31) | (1.74) | (0.72) | |||||
| Cash flow | — | — | — | (0.18) | (0.78) | (1.18) | (1.09) | (1.18) | (0.85) | (0.72) | |||||
| Capex | — | — | — | 0.00 | (0.13) | (0.10) | (0.04) | (0.01) | 0.00 | (0.01) | |||||
| Free cash flow | — | — | — | (0.18) | (0.91) | (1.27) | (1.13) | (1.19) | (0.85) | (0.73) | |||||
| Book value | — | — | — | 1.41 | (2.03) | 3.40 | 1.66 | 0.44 | 2.09 | 0.98 | |||||
| Shares, m | — | — | — | 29 | 12 | 19 | 29 | 29 | 32 | 53 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | ||||
| P/S | — | — | — | 661.64 | 661.64 | 1,180.70 | 408.14 | — | — | — | |||||
| P/B | — | — | — | 0.00 | 0.00 | 2.30 | 1.07 | — | — | — | |||||
| EV/Sales | — | — | — | 473.49 | 473.49 | 527.76 | 18.19 | — | — | — | |||||
| EV/FCF | — | — | — | (3.43) | (3.43) | (2.74) | (0.07) | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (5) | (9) | (22) | (31) | (34) | (27) | (38) | ||||
| Capex | — | — | — | 0 | (1) | (2) | (1) | 0 | 0 | (1) | |||||
| Free cash flow | — | — | — | (5) | (11) | (24) | (33) | (35) | (27) | (39) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 44 | 30 | 80 | 66 | 23 | 66 | 112 | ||||
| Total debt | — | — | — | 0 | 1 | 1 | 21 | 21 | 12 | 47 | |||||
| Net debt | — | — | — | (45) | (34) | (82) | (49) | (14) | (90) | (73) | |||||
| Shareholders’ equity | — | — | — | 41 | (24) | 64 | 48 | 13 | 66 | 52 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (35.90) | (42.00) | (56.67) | (22.52) | (63.82) | (74.53) | (32.91) | ||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | 52.15 | 111.90 | (178.06) | (33.61) | (125.50) | (139.56) | (64.58) | |||||
Negative figures in brackets.
Fiscal years to Dec 2022 · latest quarter Dec 2022
Charts ten years each
Candel Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| OABI OmniAb, Inc. | $687.7M | — (loss-making) | — (loss-making) | +244.24% (above 0%: growing) | n/m | +211.16% (above 0%: growing) | 95.45% | (49.47%) | Compare |
| ANNX Annexon, Inc. | $682.5M | — (loss-making) | — | — | n/m | −26.41% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MDXG MiMedx Group, Inc | $682.2M | 111× | — (loss-making) | −34.73% (below 0%: shrinking) | n/m | −174.83% (below 0%: shrinking) | 68.96% | (28.69%) | Compare |
| CADL Candel Therapeutics, Inc. | $681.8M | — (loss-making) | — (loss-making) | 0.00% | n/m | −93.35% (below 0%: shrinking) | 0.00% | 0.00% | |
| PHAR Pharming Group N.V. Sponsored ADR | $681.6M | 62.4× | — (loss-making) | −3.22% (below 0%: shrinking) | −57.14% (below 0%: shrinking) | −183.87% (below 0%: shrinking) | 83.92% | 1.44% | Compare |
| GYRE Gyre Therapeutics, Inc. | $678.6M | — (loss-making) | — (loss-making) | −2.12% (below 0%: shrinking) | n/m | −130.45% (below 0%: shrinking) | 92.41% | (49.35%) | Compare |
| AURA Aura Biosciences, Inc. | $657.5M | — (loss-making) | — | — | n/m | −56.26% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| DSGN Design Therapeutics, Inc. | $655.9M | — (loss-making) | — (loss-making) | — | n/m | −7.00% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PRME Prime Medicine, Inc. | $654.8M | — (loss-making) | — (loss-making) | +3.50% (above 0%: growing) | n/m | +4.40% (above 0%: growing) | 100.00% | (3,750.87%) | Compare |
| Median of peers | $680.1M | — | — | −2.12% | — | −41.33% | 76.44% | (14.34%) |
Candel Therapeutics, Inc. (CADL) key facts
- Concern: Candel Therapeutics, Inc. reported a net loss of $38.2 million, or a loss of $0.72 per share, for fiscal 2025.
- Candel Therapeutics, Inc. (CADL) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- Candel Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $125,000.00.
- As of October 16, 2026, CADL traded at $8.19, a market capitalization of $681.8 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 4,857× sales.
- Return on equity was −64.6% and debt-to-equity 0.38.
- Its Piotroski F-score is 1 out of 9 and its Altman Z-score is −1.20 (distress zone) for fiscal 2022.